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Nature’s models of regeneration provide substantial evidence that a natural healing process may exist in the heart. Analogies
existing between the damaged myocardium and the developing heart strongly indicate that regulatory factors which drive
embryonic heart development may also control aspects of heart regeneration. In this context, thyroid hormone (TH) which is
critical in heart maturation during development appears to have a reparative role in adult life. Thus, changes in TH -thyroid
hormone receptor (TR) homeostasis are shown to govern the return of the damaged myocardium to the fetal phenotype.
Accordingly, thyroid hormone treatment preferentially rebuilds the injured myocardium by reactivating developmental gene
programming. Clinical data provide further support to this experimental evidence and changes in TH levels and in particular
a reduction of biologically active triiodothyronine (T3) in plasma after myocardial infarction or during evolution of heart failure,
are strongly correlated with patients morbidity and mortality. The potential of TH to regenerate a diseased heart has now been
testinginpatientswith acutemyocardialinfarctionin aphaseII,randomized,doubleblind,placebo-controlled study (theTHiRST
study).
1.Introduction
The recognition of analogies between developmental pro-
cesses and changes occurring in the damaged myocardium
has refocused research on the pathophysiology of cardiac
disease. In fact, divergent environmental stressful stimuli
as pressure overload, hypoxia, ischaemia, metabolic distur-
bances, and so forth, seem to induce a common response
of the heart which is characterized by the suppression of
the postnatal gene program, resulting in the predominance
of the fetal gene programming. The developmental switch
of the diseased myocardium is not fully understood and
much controversy surrounds this issue [1]. However, recent
research provides evidence that reactivation of the fetal
phenotype which leads to cell dediﬀerentiation may con-
stitute a permissive state for regeneration. In this context,
developmental regulators of cell diﬀerentiation/cell dedif-
ferentiation process, such as thyroid hormone (TH), may
be implicated in this response with important therapeutic
potentials[2].Infact,thereisaccumulatingevidencethatTH
while having a critical role during development may serve
a regenerative/reparative role during adult life [2, 3]. With
this evidence in mind, this paper will highlight the basic
concepts on the role of TH in the pathophysiology of heart
disease with emphasis in the ischaemic heart disease and the
potential clinical applications.
2.CardiacRemodeling:Reactivationof
the Fetal Phenotype
Cardiac remodeling is a stress response process to an index
event such as ischaemia, mechanical loading, and metabolic
alterations. Early in this process, a variety of compensatory
mechanisms are in operation, such as activation of the
inﬂammatory and neuro-hormonal systems. In the short
term, this response seems to restore cardiovascular function
to a normal homeostatic range but with time, sustained
activation of these systems can lead to end-organ damage.
One of the main characteristics of this response is the2 Journal of Thyroid Research
reactivation of the fetal gene programming that drives cells
to de-diﬀerentiate. Thus, features of fetal heart metabolism
re-emerge and include the preference of glucose metabolism
over fatty acids as substrates for energy provision while early
response genes such as c-myc and c-fos are highly expressed
with isoform switches of many other proteins, including
metabolic enzymes and sarcomeric proteins (decrease in α-
MHC expression and increase in β-MHC expression) [1, 4].
3.Why Fetal PhenotypeIsReactivated?
The physiological relevance of the return of the heart to
fetalgeneprogramming remains still adebatableissue. There
is a long held controversy and has been the source of
many false starts and therapeutic strategies which have been
abandoned over years (e.g., treatment with beta blockers
once contraindicated and currently is cornerstone therapy).
Heart failure physiologists view this as a maladaptive
response which leads to the progressive decline in cardiac
function. However, fetal reprogramming may also result
in a “low-energy state” which adapts and protects the
damagedmyocardiumuponstress [5].Infact,theremodeled
myocardium appears tobe resistant to hypoxia or ischaemia-
reperfusion injury [6, 7].
4.Return to Fetal Phenotype: An Opportunity
forRegeneration:A StrongHypothesis
Inourlaboratory, studiesoncardiomyocytecell dediﬀerenti-
ation/rediﬀerentiation processes, has led us to the hypothesis
that return to fetal phenotype and cell dediﬀerentiation
may be a prerequisite permissive state for regeneration after
stress. In fact, de-diﬀerentiated cells seem to have the ability
to proliferate and/or grow and then to re-diﬀerentiate to
specialized cells that comprise the regenerated structure or
organ [8]. This mechanism appeared early in evolution and
allowed living organisms to adapt to environmental stresses.
Thus, it has long been recognized that salamanders have the
ability to replace whole body parts or anurans can recover
body parts at the embryonic stages through induction of cell
dediﬀerentiation/rediﬀerentiation processes [9]. Mammals
retain the ability to regenerate but in a more restrictive form.
Thus, neonatal mouse heart displays a regenerative potential
early after birth in which diﬀerentiation is not complete
[10]. This regenerative potential may be regained in adult
life after stress-induced dediﬀerentiation and return to fetal
phenotype.However,theabilityofthecellstore-diﬀerentiate
may be diminished upon intense and sustained stressful
stimuli. This rediﬀerentiation “deﬁcit” may result in heart
failure, cancer, and so forth [11], while interventions which
potentially could enhance endogenous rediﬀerentiation may
restore tissue integrity and function (Figure 1).
5.TH:a Regulatorof Cell
Dedifferentiation/Redifferentiation
The molecular pathways which control cell dediﬀerentia-
tion/rediﬀerentiation process in response to stress are not
fully understood. However, recent research points out an
important physiological role of TH signaling in this process
(Figure 1).
5.1. Evidence from Evolution. It is now recognized that
important mechanisms that allowed living organisms to
adapt to the environment and evolve, may be conserved in
mammals and be of physiological and therapeutic relevance.
Amphibian metamorphosis is one the natures’ paradigms of
tissue remodeling and regeneration and this process seems
to be thyroid hormone dependent. Thus, almost 100 years
ago, JF Gudernatsch made the remarkable discovery that
equine thyroid extracts could accelerate the metamorphosis
oftadpoleintojuvenilefrogs [12].Sincethen,severalstudies,
if not all, have shown that the morphological and functional
changes of metamorphosis are the result of alterations in the
transcriptionofspeciﬁcsetsofgenesinducedbyTH.Thyroid
hormone system seems to be an ancestral hormone system
and interestingly, thyroid hormone receptor (TR) gene is
present at the base of biletarians before TH production,
indicating an important physiological role of this receptor.
Living organisms acquired the ability of producing TH with
increasing evolutionary complexity [13].
The role of TH as developmental signal which can
trigger the onset of amphibian metamorphosis has been
documented in several studies with Xenopus laevis to be an
ideal system for ascertaining the developmental roles of TH
and its receptor [14]. Interestingly, this system reveals that
regulation of TH/TR axis allows the same simple molecule
TH to induce completely opposite morphological responses
in distinct tissues. In this context, the TH receptor alpha 1
(TRα1) seems to play an important physiological role. This
receptor appears to have a dual action which is dependent
on its liganded or unliganded (with repressive action) state
[15]. Thus, at the early developmental stages in which TH is
low, TRα1 receptor is highly expressed and at its unliganded
state acts as a repressor of TH-positive-regulated genes and
prevents precocious metamorphosis [16]. At later stages, the
rise in TH levels results in the conversion of the unliganded
TRα1 to the liganded state and triggers cell diﬀerentiation
and completes metamorphosis [17].
The developmental changes of TH signaling seem to
be of important physiological relevance for the response to
stress. Thus, anurans can regenerate body parts after injury
and this regenerative ability is higher when trauma occurs
at early embryonic stages in which cell dediﬀerentiation
prevails due the repressive actions of the unliganded TRα1.
The regenerative potential is lost at later stages in which
diﬀerentiation is progressed by the rise of TH. This response
clearly shows that dediﬀerentiation may be a prerequisite for
regeneration [14]( F i g u r e1).
5.2. Evidence from Cell Based and Animal Models. Based on
the evidence obtained from the amphibian models of tissue
remodeling, we investigated the potential role of TH signal-
ing in a model of mammalian cardiac cell dediﬀerentiation/
rediﬀerentiation induced by exposure of cardiomyocytes
to stressful stimuli. Neonatal cardiomyocytes cultures wereJournal of Thyroid Research 3
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Figure 1: Schematic of the sequence of biological events occurring in response to environmental stimuli and lead to tissue restoration. In
the case of intense and sustained stressful stimuli rediﬀerentiation “deﬁcit” occurs and results in a disease state (e.g., heart failure, cancer,
etc.). Exogenous TH can enhance rediﬀerentiation and restore damage.
exposed to phenylephrine (PE, an α1-adrenergic agonist)
w h i c hi sap r o g r o w t hs t i m u l u sa n di t se ﬀects are mediated
by activation of intracellular growth kinases such as ERK
and mTOR [18]. Thus, PE administration (in the absence
of TH in the medium) resulted in marked cell dediﬀeren-
tiation: PE treated cardiomyocytes, unlike the nontreated
cardiomyocytes (which were almost of circular shape with
poorly organized cytoskeleton), appeared to be large with
disoriented, dense myoﬁbrils, and undeﬁned shape with
ﬁlopodia-like structures [19]. Myosin isoform expression
switched to a fetal pattern with a marked increase in
β-MHC expression. This response was associated with a
redistribution of TRα1 with increased content of TRα1i n
the nucleus and decreased in the cytosol and was abolished
by inhibition of activation of ERK signaling with PD98059
[19]. Furthermore, an intact mTOR signaling pathway was
found to be required for this response. In fact, inhibition
of mTOR signaling with rapamycin not only abolished PE-
inducednuclearTRα1 overexpression but resulted in marked
TRα1 decrease with cell atrophy [20]( F i g u r e2). These data
clearlyshowthatstress-induced TRα1 overexpression may be
a potential mechanism of cardiomyocyte dediﬀerentiation.
Transfection and pharmacological cell-based studies and
studies in animals provide further support to this notion.
Thus, overexpression of unliganded TRα1i nn e o n a t a lc a r -
diomyocytes resulted in cell growth with fetal pattern of
myosin isoform expression [21], and cardiomyocytes from
mice with dominant negative TRα1 displayed impaired
calcium handling and contraction [22]. Similarly, pharma-
cologicalinhibition ofT3 binding to TRα1 prevented cardiac
embryonic cells diﬀerentiation [19]. In accordance to this
evidence, TRα1 overexpression was shown to occur during
the development of pathological hypertrophy after myocar-
dial infarction in rats and decline with the progression to
heart failure [20]. Further support to the role of TRα1a s
a critical regulator of cell dediﬀerentiation/rediﬀerentiation
in response to stress was provided by the eﬀects of addition
of TH in the medium of cells stressed by PE. Thus, as in
anurans, we raised the levels of T3 in the medium to convert
the unliganded TRα1 to a liganded receptor. Interestingly,
thisresultedin cellrediﬀerentiationasthiswasevidentbythe
switch of fetal-like pattern of MHC expression to the adult
pattern and changes in cell morphology: cells displayed an
elongated shape, with a ﬁlamentous actin pattern organized
into orderly arrays [19]( F i g u r e2).
6.THPromotesEndogenousRegenerationof
the Damaged Heart
On the basis of the evidence obtained from cell and animal
models it seems likely that treatments targeting the TH4 Journal of Thyroid Research
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Figure 2: Cardiac cells are de-diﬀerentiated upon exposure to progrowth stimuli such as phenylephrine (PE). This response is mediated
via ERK/TRα1 and requires an intact mTOR signaling. Inhibition of mTOR signaling with rapamycin not only abolishes PE-induced
nuclear TRα1 overexpression but results in marked TRα1 decrease with cell atrophy. De-diﬀerentiated cells retain the ability to re-
diﬀerentiate when T3 is added to the medium. TRα1 by its dual action (liganded versus unliganded) seems to act as a regulator of the
cell dediﬀerentiation/rediﬀerentiation process.
signaling may promote endogenous regeneration of the
damaged myocardium [23]. Several lines of experimental
evidence support this notion [24–29]( F i g u r e3). Thus,
TH treatment early after infarction resulted in marked
improvement of contractile indices independent of loading
conditions, such as +dp/dt and −dp/dt, due to favorable
cell remodeling as indicated by the switch of MHC isoform
expression from the fetal to adult pattern [26]. Furthermore,
TH increased cardiac mass and normalized wall stress while
it preserved left ventricular geometry to the ellipsoidal
shape. These important structural and functional changes
were translated to enhanced myocardial performance as
indicated by signiﬁcant improvement of left ventricular
ejection fraction [27]. Similar eﬀects were evident even
after the development of pathological hypertrophy in old
myocardial infarction. In fact, TH was shown to have the
ability to convert pathological to physiological hypertrophy
[30]( F i g u r e3).
7.TH andCell Differentiation:
PotentialUnderlyingMechanisms
Cell diﬀerentiation seems to be a redox regulated process.
This mechanism has been demonstrated in cultures of
glial oligodendrocyte/astrocyte progenitor cells in which the
more oxidizing cytoplasmic environment induced by growth
factors such as thyroid hormone and bone morphogenic
protein 4 and the chemical oxidant tert-butyl hydroperoxide
favored cell oligodendrocyte formation. By contrast, a more
reducing cytoplasmic environment induced by growth in
the presence of a basic ﬁbroblast growth factor, platelet-
derived growth factor, or their combination favored the
maintenance of the progenitor cells [31]. Similarly, the
induction of cardiac hypertrophy by TH is shown to involve
redox regulated signaling pathways [32]. Furthermore, TH
can alter cardiac cell shape and growth via activation of
distinct growthkinase signaling pathways. Thus, TH involves
ERKsignalingtochangecellshapeandgeometrywhereascell
growth is an mTOR-dependent process [33].
8.The TH“Paradox”
It is now recognized that cell diﬀerentiation and cell survival
may share common signaling pathways. Thus, the TH-
induced activation of redox-regulated signaling pathways
which mediate cell diﬀerentiation, results also in the up-
regulation of redox-regulated cardioprotective molecules,
such as heat shock proteins which can increase tolerance
of the cell against ischaemia [34, 35]. Furthermore, TRα1
receptorwhichiscriticalincelldiﬀerentiationappearsalsoto
mediate TH-induced cardioprotection (unpublished data).
These data provide an explanation regarding the paradoxJournal of Thyroid Research 5
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treated hearts (b). TH shortly after myocardial infarction induces favorable changes in left ventricular chamber remodeling in a time-
dependent manner; TH treatment accelerates the development of cardiac hypertrophy which normalizes wall tension and reshapes left
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of TH being rather protective than detrimental for the
ischaemic heart although it increases oxygen consumption
(by accelerating heart rhythm and increasing cardiac con-
tractility) and depletes the heart from glycogen [36]. Here,
it should be noted that the protective eﬀect of TH has also
been observed in models of neuronal injury [37].
9.Does THAvailabilityfora Diseased Human
MyocardiumRepresenta CriticalPoint?
As clearly documented by several experimental animal
data, most of the eﬀects of TH on cardiac function are
mediated by binding of biologically active T3 to nuclear
TR. Thus, T3 tissue concentration represents the switching
factor in TH signalling. Not surprisingly, in patients with
primary thyroid mild dysfunction, cardiovascular adverse
manifestations have widely been described [38, 39]. An
altered TH bioavailability has also been documented in
cardiac patients without primary thyroid disorders. The
most frequent change in TH metabolism in patients with
severe cardiac disease including heart failure, myocardial
infarction, and coronary artery bypass is a signiﬁcant fall
in circulating biologically active T3 and a corresponding
increase in reverse T3 (rT3), the inactive T3 metabolite[40,
41]. The low-T3 syndrome occurs in approximately 20–
30% of patients with heart failure [42–44] with signiﬁcantly
higher incidence in patients with NYHA functional class III-
IV than in those with NYHA I-II [43, 45]. The occurrence of
a low T3 syndrome, however, does not represent a peculiar
pattern of cardiac disease because it has been documented
in several noncardiac illnesses. The underlying pathophys-
iological mechanisms are the reduced enzyme activity of
5  monodeiodinase responsible for converting T4 into T3
and the increased enzyme activity of 5 monodeiodinase
responsible for converting T4 into the inactive r-T3 in pe-
ripheral tissues [46].
Regardless of the cause, type (i.e., acute or chronic), se-
verity, and time course of the disease, the ﬁrst and dominant
pathophysiological hypothesis on the meaning of low-T3
syndrome was that decreased T3 concentrations are merely
the result of an adaptive process ﬁnalized to reduce energy
expenditure and thus, having beneﬁcial eﬀects through the
reductionin metabolic demand [47].However, experimental
and clinical evidence challenged this interpretation. In an ex
vivo study on human myocardial biopsies, we demonstrated
that long-term T3 deprivation negatively aﬀected both
overall tissue architecture of cultured myocardial slices and
calcium handling of the outgrowing cardiomyocytes [48]
(Figure 4), indicating that a low-T3 state, as observed
during evolution of cardiac disease, can be considered a
true hypothyroid-like cardiac condition that worsens per
se cardiomyocyte remodeling and dysfunction. In line with
the above interpretation, clinical observational studies have
shown the important negative prognostic impact of low-
T3 syndrome in patients after acute myocardial infarction
and cardiopulmonary bypass and during evolution of heart
failure [49, 50]. A negative correlation was also found
between plasma FT3 concentrations and the extent of
myocardial damage after AMI [51].
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Figure 4:Structural andphenotypic eﬀects of T3 supplementation.
After 10 days of culture, T3-supplemented myocardial fragments
presented better preserved cardiomyocytes both at histological (a)
and immunohistochemical examination (c). Weaker staining and
progressive atrophy was observed in the corresponding untreated
samples ((b) and (d), resp.). Myocardial sections were stained
hematoxylin eosin (a), (b) for total protein content evaluation or
immunostained for α-sarcomeric actinin (c), (d) for sarcomeric
specif protein content. Images were acquired with a CCD camera
and optical density was measured (scale bar = 50μm). (e) Quan-
tiﬁcation of the histological results obtained from hematoxylin-
eosin and α-sarcomeric-actinin staining of 10-day-old human
myocardium in culture. P was determined using the two-tailed
unpaired Student’s t-test; data are expressed as mean ± SEM
(experimental data derived from [28]).
Independently of the parameter used (i.e., a reduction
in circulating levels of T3, an increase in inactive rT3, a
low free T3 index/rT3 ratio, and an free T3/free T4 ratio),
previous works showed that an altered peripheral TH path-
way was in any case associated with high incidence of fatal
events consisting of cardiac or cumulative death, or heart
transplantation [42, 43, 52]. In a study from our laboratoryJournal of Thyroid Research 7
the probability of death, either cardiac or cumulative, was
signiﬁcantly higher in patients with than without low-T3
syndrome [53]. In another study that enrolled 281 in-
patientswithischemicandnonischemic heart[45],wefound
that total T3 and left ventricular ejection fraction were the
onlyindependentpredictivevariablesatmultivariateanalysis
of both cardiac and cumulative death. More recently, these
results have been conﬁrmed in a larger cohort of patients
with low-T3 syndrome being the cardiac and overall deaths,
respectively, 3.4% and 7.3% in euthyroidism, and 6.5% and
13.1% in low-T3 syndrome patients [54].
10.THTherapyinPatientswithHeartDisease
10.1. General Considerations. Besides experimental ﬁndings
on animal studies, several lines of evidencesuggest that some
components of the TH signaling could be impaired also in
dysfunctioning human heart.
Important acquisitions of knowledge have been derived
from a pioneering experiment in a patient with severe
hypothyroidism and heart failure in whom several myocar-
dial biopsieswere taken; during hypothyroidism MHC alpha
mRNA was markedly lower with the opposite for MHC beta.
Also phospholamban was 10-fold higher in the hypothyroid
heart when compared with euthyroidheart. With restoration
of euthyroidism all changes reverted to normal and a normal
cardiac function was restored [55]. These direct in vivo
human observations are the basis of the afterwards so-called
activation of a fetal gene program otherwise indicated as
“recapitulation of the fetal phenotype” [56, 57]s e c o n d a r y
to the hypothyroid state, all contributing to the decreased
contractile function typical of adult HF and a reversal of
genotype/phenotype to a more fetal-like cardiac state.
Notably, in a therapeutic perspective, the activation of
the fetal gene program observed during evolution of heart
failure in adult life appears to be potentially reversible when
the TH proﬁle is normalized. The restoration of a phys-
iological TH/TR interaction might counteract progression
of heart disease by diﬀerent mechanisms including: (1) a
positive remodelling through the modulation of myocardial
gene expression; (2) an improvement in cardiac systolic
and diastolic function with a consequent improvement
in haemodynamics; (3) an improvement in myocardial
perfusion. Last but not least, a positive eﬀect on quality of
life by combining multisystems actions of the TH. Actually
the rationale for systemic administration of TH is based
on the additional systemic actions of THs, in particular on
skeletal muscle, kidney, and brain that could be important
componentsoftheprogressionfromorgan-limitedtowhole-
body disease.
10.2. TH-Based Therapy in Cardiac Patients: From Fear to
Hope. Treatment with TH represents a challenging ﬁeld
in cardiac patients with an altered TH metabolism. The
potential of novel TH therapies that address the molecular
biology of thyroid dysfunction and heart disease represents
thus an attractive area of multidisciplinary interest. Based
on the available experimental evidence the ﬁnal goal of
TH-based treatment should be to restore and maintain
over time a physiological thyroid state when an altered
TH metabolism and action does occur as in postischemic
remodeling. On the other hand, in normal, nonischaemic
heart, excessive TH may produce several cardiovascular
deleterious manifestations including increased heart rate,
susceptibilityto atrial and ventricular arrhythmias, increased
oxygen demand, and cardiac hypertrophy both in humans
and animals [58, 59]. Subjects with long-term TH excess
may also develop cardiac hypertrophy caused by both direct
eﬀectsofTH on functional contractile and structural protein
synthesis as well as indirectly by increasing cardiac load [60].
In addition, long-term L-T4 treatment has been shown to
produce signiﬁcant left ventricular hypertrophy and increase
in left ventricular mass index [61]. TH excess has been also
implicated as primary cause of impaired cardiopulmonary
exercise tolerance probably due to a reduction in cardiac
functional reserve [60]. The mechanisms of transition
from cardiac hypertrophy to heart failure, however, still
remain largely unclear [59]. An increase in LV mass has
also been reported in long-term thyroid hyperactivity and
could counteract the beneﬁcial eﬀect of TH on diastolic
performance by worsening diastolic ventricular ﬁlling and
systolic performance on eﬀort [62]. Moreover, long-term
TH overload may enhance the sensitivity of myocardium to
catecholaminesandincreasetheactivityofrenin-angiotensin
system in myocardium [63]. Consequently, chronically ele-
vated catecholamines and/or angiotensin II in myocardium
may reduce cardiac contractility and promote apoptosis
of cardiomyocytes in humans and animals [64]. By these
premises, it is not surprising that some patients with
endogenous or exogenous subclinical hyperthyroidism may
show signiﬁcant changes in echocardiographic parameters
associated with systolic and diastolic dysfunction, both
potentially contributing to increased cardiovascular risk
[65, 66]. The small number of patients and the lack of
control [65] of the above studies may limit, however, the
clinical relevance of data. Observational, large-scale studies
on relationships between cardiovascular morbidity and mor-
tality in exogenous subclinical hyperthyroidism induced by
long-term LT4 treatment have yielded, however, conﬂicting
results [67] and only in patientswith endogenoussubclinical
hyperthyroidism an increased risk of nonfatal morbidity
and dysrhythmia has been reported [68]. An increased
cardiovascular and cerebrovascular mortality has also been
described in a community-based review of subjects with
subclinical hyperthyroidism followed over a 10-year period
[69]; the role of dysrhythmias may be critical in accounting
for some of the excess cardiovascular and cerebrovascular
mortality observed in those patients [70].
The emerging clinical and experimental knowledge,
t a k e na saw h o l e ,s u g g e s t st h a tT Ht r e a t m e n tm a yp r o v i d e
more beneﬁcial than harmful eﬀects including reversal
and/or limitation of remodeling, and progression to cardiac
dysfunction.However,despiteindicationsonpositiveactions
of restoring a physiologic TH signalling in a damaged heart,
interventional trials by the use of THs or THs analogs
have been largely discouraged in cardiac patients. Common
belief of physicians is that exogenous TH (or TH analogue)8 Journal of Thyroid Research
therapy represents in any case an injudicious and dangerous
approach with risk of arrhythmia, myocardial ischemia/
infarction, and worsening of congestive heart failure. The
origin of this belief is, however, largely debatable and mostly
based on results from the Coronary Drug Project (CDP)
study [71].
CDP demonstrated adverse outcomes, particularly in
regards to the proarrhythmic eﬀects of Dextro (D)-T4
[71].The D-T4 preparation (Choloxin, Flint Laboratories)
used in the CDP was contaminated with a high level
of active L-T4 [72]. Therefore, the cumulative dose of
administered L-T4 was toxic, being equivalent to several
times the L-T4 dose that would be given to a patient to
correct hypothyroidism. For this reason, the CDP did not
provide helpful information regarding the therapeutic use
of physiological TH in the treatment of cardiac patients. To
ourknowledge,all pilotinterventionalstudieswiththeuseof
syntheticTHconductedincardiacdisease havesuggested,on
the contrary, its safety [50, 73] and provided some evidence
for beneﬁcial eﬀects, mainly in patients undergoing cardiac
surgery as well as in those with heart failure with or without
cardiogenic shock [50, 73–77]. Type, dosage, and timing of
TH-based treatment still remain, however, important open
issues which are awaited to be addressed in clinical trials.
10.3. TH-Based Therapeutic Strategies in Cardiac Patients.
From a theoretical point of view, therapeutic strategies that
can be employed to optimize TH signalling in the presence
of HF can be summed up in the following ﬁve points:
(1) administration of synthetic L-T4; using this approach
the main physiological pathway of secretion and peripheral
metabolism of TH system is preserved; (2) administration
of synthetic L-T3: by this way the physiological pattern of
peripheral conversion from T4 into T3, which is impaired in
presence of a low-T3 syndrome, is bypassed through direct
application of the biologically active TH; (3) administration
ofaTHanalogue,thatis ofasyntheticand, asmuchpossible,
cardiotropic compound showing similar positive eﬀectsthan
the natural TH but lower adverse eﬀects; (4) genetic manip-
ulation of the expression of cardiovascular deiodinases: in
this case the main goal is to increase local production
and bioavailability of T3; (5) genetic manipulation of the
cardiovascular TR pattern: in this case the goal is to increase
hormonal signalling at the receptorlevel while preserving T3
availability. At present, the ﬁrst three approaches have been
applied in a few human studies, and with a low number of
patients [78–80] whereas the remaining therapeutic options
are still in the experimental animal stage [81, 82].
10.4. L-T4 Administration. Moruzzi et al. published two
studies in which synthetic L-T4 was given orally at the
“physiological” dose of 0.1mg per day and cardiovascular
eﬀects were assessed after short-term (one-week) treatment
and after continuous three-month treatment [79, 83]. In
particular, the latter is the only published study that tried to
assess the long-term eﬀects of TH in a model of randomised
placebo versus L-T4 therapy study. In both studies L-T4
was well tolerated and induced signiﬁcant improvement
in cardiac pump function, consisting of enhanced resting
LVEF, resting cardiac output, and functional capacity during
exercise.
10.5. L-T3 Administration. Inthe pioneerstudy byHamilton
etal.aprotocolbasedonadministration ofintravenousbolus
dose followed or not by a few hours of L-T3 infusion in
patients with advanced HF and low T3 levelsand/or elevated
rT3 concentrations was adopted [78]H o w e v e r ,t h es t u d y ’ s
main weakness was the wide variability in scheduled time
and dose of the administered L-T3 (cumulative dose from
0.15 to 2.7μg/kg with infusion time ranging from a mini-
mum of 6 to a maximum of 12h) in a small, nonrandomized
patient population. Although circulating T3 obtained after
L-T3 administration was widely variable and in all cases
clearly above the upper limit of normal range, no side eﬀects
(i.e., no myocardial ischemia or complex arrhythmias) have
been documented. In particular, in patients who received the
largest doses of L-T3, cardiac output improved signiﬁcantly
starting from 2hafter administration withaparallel decrease
in systemic vascular resistance. Importantly, heart rate did
not change nor did metabolic demand as assessed by
indirect calorimetry. Nevertheless, the administration of L-
T3 at high doses, mimicking a hyperthyroid status, may be
detrimental when used for long term. In fact, experimental
data clearly documented that high doses of L-T3 were able
to induce myocardial hypertrophy, and that they were only
initially associated with an improved cardiac performance,
but followed by a decline after 1 month of treatment [84].
This ﬁnding was also associated with increased expression
of uncoupling proteins (UCP2 and UCP3) which may be
responsible for the decrease in mitochondrial eﬃciency
during thyroid hyperfunction [85].
In a pilot study from our laboratory L-T3 was admin-
istered at a “physiological” dose of 20μg/day/m2 body
surface for a period of 96 h in six patients with advanced
heart failure and low-T3 syndrome who were undergoing
stable conventional treatment and salt intake. L-T3 constant
infusion inducedaprogressivereductioninsystemic vascular
resistance and an increase in left ventricular ejection fraction
and cardiac output, the latter invasively monitored by Swan-
Ganz catheter; urinary output also improved, whereas no
changes in heart rate and systemic arterial BP were observed
[78–80]. An improvement in overall cardiac performance as
documented by an increased stroke volume and left ven-
tricular end-diastolic diameter, all noninvasively assessed by
c a r d i a cm a g n e t i cr e s o n a n c ei m aging, was also documented
after3-dayL-T3substitutiveinfusion in aplacebo-controlled
study on patients with chronic and clinically stable dilated
cardiomyopathy and low-T3 syndrome. Importantly, the
improvement in cardiac performance was not associated
with an increase in myocardial O2 consumption, nor there
was an increase in total cardiac work. Also the concomi-
tant evidence for a neuroendocrine deactivation, probably
contributing to the improved hemodynamic conditions, as
documented by the decrease in noradrenaline circulating
plasma levels and of the counterpart NT-proBNP secondary
to L-T3 treatment in patientswith heart failure needs further
explorationinfuturestudies.Inconclusion,overalltheaboveJournal of Thyroid Research 9
observations suggest that the modality of the therapeutic
approach is likely the key point when testing TH treatment
in cardiac patients with nonthyroidal illness.
10.6. Thyroid Hormone Analogues Administration. In 1992,
a TH analogue (DITPA) showed cardiac inotropic selec-
tivity comparable to TH itself, accompanied by minimal
eﬀects on heart rate and metabolic activity [86]. Long-term
administration of DITPA seems also to stimulate coronary
arteriolar growth without inducing cardiac hypertrophy,
by upregulating key angiogenic growth factors [87]. The
rationale of using DITPA was to avoid the detrimen-
tal eﬀects of exogenously administered TH, such as an
increase in heart rate and body metabolism (3). While the
rationale appears logical, the results in human studies do
not appear so favourable. In a pilot randomized DITPA
versus placebo clinical study, DITPA was administered in
patients with NYHA functional class II-III for 2–4 weeks
at a dosage of 1.87–3.75μg/Kg body weight per day. The
major hemodynamic eﬀe c t sc o n s i s t e di ni m p r o v e dc a r d i a c
index and decreased systemic vascular resistance index.
Further, diastolic function was ameliorated as documented
by the decrease in the isovolumetric relaxation time which
is a parameter of diastolic cardiac relaxation properties
[88].
In a very recent placebo-controlled study by Goldman
et al. [89]. The TH analogue 3,5 diiodothyropropionic acid
(DITPA) was administered in patients with congestive heart
failure. DITPA induced an increase in both cardiac index
and heart rate associated with a reduction in systemic
vascular resistance. However, no improvement on outcome
o rs y m p t o m sw a so b s e r v e d ,b u tr a t h e rf a t i g u ew a sm o r e
frequent in the DITPA Group. Importantly, weight loss,
increased heart rate, fatigue, reduction in serum cholesterol,
and suppressed TSH, all well-known signs and symptoms of
thyrotoxicosis, suggest an excess of TH action induced by
DITPA at the doses utilized in that study [90].
10.7. Genetic Manipulation. Emerging experimental data
encourage the adoption of a new target-organ strategy based
on genetic manipulation. In this way it is somewhat possible
to overcome all the limitations related to a systemic adminis-
tration of synthetic native hormone or TH analogues. In the
rat model of pressure overload induced cardiac dysfunction,
the enhancement of T3 signalling by increased deiodinase
Type 2 activity or TR expression has been linked to improve
cardiac contractile function and prevention of HF [81, 82].
In particular, the mechanism for preventing HF may depend
on avoiding the reversion from an adult to a fetal gene-
like state, that is, the shift from α-MCH to β-MCH and
decreased SERCA2, which has also been demonstrated in
the human failing heart in response to hypothyroidism.
Moreover, discovery in human VSM cells and in animal
microcirculatory system of a deiodinating pathway able to
produce local T3 with vasodilating action [91, 92]c o n ﬁ r m s
that the vascular system is also a direct target of TH and may
be a potential point of genetic manipulation to modulate
vascular peripheral resistance during evolutionof HF.
11.Conclusions
Overall available data on patients with cardiac patients
treated with synthetic THs suggest that most of the observed
eﬀects on cardiac performance can be explained on the
basis of both genomic and nongenomic TH direct actions
on cardiac and vascular systems, perfectly in line with our
knowledge on cellular mechanisms induced by TH.
On the basis of the above-mentioned experimental and
clinical ﬁndings, in 2009 we started a phase II, random-
ized, double blind, placebo-controlled study by the use
of substitutive doses of synthetic L-triiodothyronine in
patients with STEMI (ST-Elevation Myocardial Infarction)
and borderline/reduced circulating T3 [93]. Treatment with
synthetic TH or placebo starts during the in hospital period
in presence of stable haemodynamic conditions (i.e., 48–
72hrs after STEMI) and will be taken for further 6 months
after hospital discharge (Chronic phase). Actually, while in-
hospital mortality from acute MI has declinedin recent years
duetoimprovedearlyintervention,theﬁve-yearrateofheart
failure has increased in these patient [94]. Furthermore,
severe diastolic dysfunction is a strong predictor of one-
year rehospitalisation in MI survivors [95]. It is thus likely
that TH treatment will speciﬁcally target chamber dilatation
and diastolic dysfunction by its beneﬁcial eﬀects on cardiac
perfusion, architecture and function. Primary objectives of
the study are to investigate:
(1) the safety and feasibility of synthetic TH replacement
in patients with STEMI;
(2) TH replacement therapy eﬀects on postischemic
remodelling and LV function;
(3) the eﬀects of TH replacement therapy on clinical
outcome in terms of major (cardiac and non cardiac
death, reinfarction) and minor (recurrence of angina,
coronary revascularization, and hospital readmis-
sion) events.
S e c o n d a r yo b j e c t i v e so ft h es t u d ya r et oe v a l u a t et h e
eﬀects of thyroid hormone therapy on
(1) infarct size, regional wall motion abnormalities,
systolic, and diastolic myocardial function;
(2) neuroendocrine imbalance;
(3) patients functional capacity, quality of life, cognitive
and behavioural status.
When available, data from the above study will help to
clarify the potential clinical usefulness of TH treatment as
a novel strategy to protect a damaged myocardium from
pathological growth and remodelling after an acute ischemic
insult.
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